<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467335</url>
  </required_header>
  <id_info>
    <org_study_id>206280</org_study_id>
    <secondary_id>AI438-053</secondary_id>
    <nct_id>NCT02467335</nct_id>
  </id_info>
  <brief_title>Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <brief_summary>
    <textblock>
      A single oral dose study in subjects with hepatic impairment and healthy control subjects.
      Subjects will stay at the clinical facility where interval blood samplings will be obtained
      and examined for drug effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2015</start_date>
  <completion_date type="Actual">October 3, 2015</completion_date>
  <primary_completion_date type="Actual">October 3, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of hepatic impairment on the single-dose peak plasma concentration Cmax of BMS-626529 (metabolite).</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (INF) of BMS-626529 (metabolite).</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (0-T) of BMS-626529 (metabolite).</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of a 600-mg single dose of BMS-663068 in subjects with hepatic impairment and in healthy subjects through analysis of adverse events.</measure>
    <time_frame>5 days</time_frame>
    <description>Adverse events will be arranged by system organ class, preferred term and hepatic function group. In addition, electrocardiogram readings will be summarized by time point relative to hepatic function group, and investigator-identified abnormalities, if present, will be listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between the Child-Pugh classification (including its components) as well as liver function tests and BMS-626529 profile PK parameters.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Impaired Subjects - Mild Rating</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Impaired Subjects - Moderate Rating</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Impaired Subjects - Severe Rating</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Hepatic Impaired Subjects - Moderate Rating</arm_group_label>
    <arm_group_label>Hepatic Impaired Subjects - Severe Rating</arm_group_label>
    <arm_group_label>Hepatic Impaired Subjects - Mild Rating</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, ages 18 to 70 years, inclusive

          -  BMI: 18.5 to 38 kg/m2

          -  Body weight great or equal to 45.5 kg

          -  Subjects with hepatic impairment

          -  Subjects with hepatic impairment must be on a stable dose of medication and/or
             treatment regimen

          -  Healthy subjects to the extent possible matched to the first four subjects with
             hepatic impairment with regard to age, body weight, and sex, as determined by no
             clinically significant deviation from normal in medical history, physical examination,
             ECGs, and clinical laboratory determinations

        Exclusion Criteria:

          -  Any major surgery within 4 weeks of study drug administration

          -  Donation of blood to a blood bank or in a clinical study (except a screening visit)
             within 4 weeks of study drug administration (within 2 weeks for plasma only)

          -  Subject has required additional medication for hepatic encephalopathy within 12 months
             (6 months for severe hepatic impairment) prior to dosing

          -  Presence of severe ascites or edema in subjects, as judged by the PI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

